Vol. 3, Issue 5 (2017)
Evaluation of different factors associated with Dipeptidyl-4 inhibitors use in diabetic patients
Author(s): Dr. Santosh Kumar, Dr. Abha Kumari
Abstract: Introduction: The commonly used anti-diabetic drugs currently do not deal with major pathophysiological issues. Biguanides repress the hepatic glucose production, Sulfonylureas and Glinides stimulate the insulin secretion, α-glucosidase inhibitors delays digestion and absorption of intestinal carbohydrates and Thiazolidinediones and Metformin increase the sensitivity to insulin and peripheral glucose uptake. The present study was planned to assess the various factors associated with the use of Dipeptidyl-4 inhibitors in patients with type 2 diabetes mellitus. Materials and methods: Clinical and demographic parameters were collected from each subject. Parameters included in demographic data were age, gender, ethnicity, weight, height, and body mass index (BMI). Parameters for clinical data regarding T2DM were year of diagnosis, hbA1c conc., and either FPG or RPG concentration. Class and name of drug and dosage and date of prescribed DPP-4 inhibitors for treatment of T2DM were also recorded. Results: For the study, 120 patients were selected after following the inclusion and exclusion criteria strictly. Of the 120 subjects, 66 (55%) were females and 54 (45%) were males. The mean age of the subjects was 62 years (range, 22 to 89 years). Of the total 120 patients, 103 patients were prescribed Sitagliptin and 17 patients were prescribed Vildagliptin. Conclusion: Patient age and concurrent use of beta blockers were statistically significant factors in the present study associated with prescribing DPP-4 inhibitors.